Earlier Bimekizumab Use Lifts 3-Year HS Clearance in BE HEARD EXT
Post hoc BE HEARD EXT data presented at EADV 2026 show 47.4% IHS4-100 at 3 years when bimekizumab starts under 2.38 years after HS diagnosis, versus 33.3% beyond 10.74 years.
Topic
Be Heard Trial
Topic